Lower Blood Glucose, Hyperglucagonemia, and Pancreatic Alpha Cell Hyperplasia in Glucagon Receptor Knockout Mice

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 Jan 29

PMID 12552113

Citations 266

Authors

R W Gelling

X Q Du

D S Dichmann

J Romer

H Huang

L Cui

S Obici

B Tang

J J Holst

C Fledelius

P B Johansen

L Rossetti

L A Jelicks

P Serup

E Nishimura

M J Charron

Affiliations

Soon will be listed here.

Abstract

Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic alpha cells in response to low blood glucose. To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor (Gcgr(-/-)). These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared with control animals. Gcgr(-/-) mice displayed supraphysiological glucagon levels associated with postnatal enlargement of the pancreas and hyperplasia of islets due predominantly to alpha cell, and to a lesser extent, delta cell proliferation. In addition, increased proglucagon expression and processing resulted in increased pancreatic glucogen-like peptide 1 (GLP-1) (1-37) and GLP-1 amide (1-36 amide) content and a 3- to 10-fold increase in circulating GLP-1 amide. Gcgr(-/-) mice also displayed reduced adiposity and leptin levels but normal body weight, food intake, and energy expenditure. These data indicate that glucagon is essential for maintenance of normal glycemia and postnatal regulation of islet and alpha and delta cell numbers. Furthermore, the lean phenotype of Gcgr(-/-) mice suggests glucagon action may be involved in the regulation of whole body composition.

Citing Articles

Blockade of glucagon receptor induces α-cell hypersecretion by hyperaminoacidemia in mice.

Jia J, Bai X, Kang Q, Jiang F, Wong F, Jin Q Nat Commun. 2025; 16(1):2473.

PMID: 40075066 PMC: 11903786. DOI: 10.1038/s41467-025-57786-7.

Islet hormones at the intersection of glucose and amino acid metabolism.

White P, Wewer Albrechtsen N, Campbell J Nat Rev Endocrinol. 2025; .

PMID: 40055529 DOI: 10.1038/s41574-025-01100-4.

Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH-promoting GAN diet and a high-fat diet.

Galsgaard K, Elmelund E, Hunt J, Smits M, Grevengoed T, Christoffersen C Physiol Rep. 2025; 13(4):e70235.

PMID: 39985139 PMC: 11845321. DOI: 10.14814/phy2.70235.

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.

Hyperaminoacidemia from interrupted glucagon signaling increases pancreatic acinar cell proliferation and size via mTORC1 and YAP pathways.

Dai C, Zhang Y, Gong Y, Bradley A, Tang Z, Sellick K iScience. 2024; 27(12):111447.

PMID: 39720531 PMC: 11667045. DOI: 10.1016/j.isci.2024.111447.

References

Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H . A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine.... J Biol Chem. 1997; 272(47):29911-8. DOI: 10.1074/jbc.272.47.29911. View

Furuta M, Yano H, Zhou A, Rouille Y, Holst J, Carroll R . Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A. 1997; 94(13):6646-51. PMC: 21212. DOI: 10.1073/pnas.94.13.6646. View

Furuta M, Carroll R, Martin S, SWIFT H, Ravazzola M, Orci L . Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem. 1998; 273(6):3431-7. DOI: 10.1074/jbc.273.6.3431. View

Porte Jr D, Seeley R, Woods S, Baskin D, Figlewicz D, Schwartz M . Obesity, diabetes and the central nervous system. Diabetologia. 1998; 41(8):863-81. DOI: 10.1007/s001250051002. View

Madsen P, Knudsen L, Wiberg F, Carr R . Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem. 1998; 41(26):5150-7. DOI: 10.1021/jm9810304. View

Parker J, Andrews K, Allen M, Stock J, McNeish J . Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun. 2002; 290(2):839-43. DOI: 10.1006/bbrc.2001.6265. View

Webb G, Akbar M, Zhao C, Swift H, Steiner D . Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes. 2002; 51(2):398-405. DOI: 10.2337/diabetes.51.2.398. View

Zhou A, Webb G, Zhu X, Steiner D . Proteolytic processing in the secretory pathway. J Biol Chem. 1999; 274(30):20745-8. DOI: 10.1074/jbc.274.30.20745. View

Kieffer T, Habener J . The glucagon-like peptides. Endocr Rev. 1999; 20(6):876-913. DOI: 10.1210/edrv.20.6.0385. View

10.

Fosgerau K, Westergaard N, Quistorff B, Grunnet N, Kristiansen M, Lundgren K . Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice. Arch Biochem Biophys. 2000; 380(2):274-84. DOI: 10.1006/abbi.2000.1930. View

11.

Baggio L, Kieffer T, Drucker D . Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 2000; 141(10):3703-9. DOI: 10.1210/endo.141.10.7720. View

12.

Holst J . Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Regul Pept. 2000; 93(1-3):45-51. DOI: 10.1016/s0167-0115(00)00185-3. View

13.

Drucker D . Minireview: the glucagon-like peptides. Endocrinology. 2001; 142(2):521-7. DOI: 10.1210/endo.142.2.7983. View

14.

Wang J, Xu J, Finnerty J, Furuta M, Steiner D, Verchere C . The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes. 2001; 50(3):534-9. DOI: 10.2337/diabetes.50.3.534. View

15.

Le Roith D, Zick Y . Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 2001; 24(3):588-97. DOI: 10.2337/diacare.24.3.588. View

16.

Dolnikoff M, Martin-Hidalgo A, Machado U, Lima F, Herrera E . Decreased lipolysis and enhanced glycerol and glucose utilization by adipose tissue prior to development of obesity in monosodium glutamate (MSG) treated-rats. Int J Obes Relat Metab Disord. 2001; 25(3):426-33. DOI: 10.1038/sj.ijo.0801517. View

17.

Friis-Hansen L, Lacourse K, Samuelson L, Holst J . Attenuated processing of proglucagon and glucagon-like peptide-1 in carboxypeptidase E-deficient mice. J Endocrinol. 2001; 169(3):595-602. DOI: 10.1677/joe.0.1690595. View

18.

Yu S, Castle A, Chen M, Lee R, Takeda K, Weinstein L . Increased insulin sensitivity in Gsalpha knockout mice. J Biol Chem. 2001; 276(23):19994-8. DOI: 10.1074/jbc.M010313200. View

19.

Rall L, Pictet R, Williams R, Rutter W . Early differentiation of glucagon-producing cells in embryonic pancreas: a possible developmental role for glucagon. Proc Natl Acad Sci U S A. 1973; 70(12):3478-82. PMC: 427263. DOI: 10.1073/pnas.70.12.3478. View

20.

Katz J, Golden S, Wals P . Stimulation of hepatic glycogen synthesis by amino acids. Proc Natl Acad Sci U S A. 1976; 73(10):3433-7. PMC: 431129. DOI: 10.1073/pnas.73.10.3433. View